Innate and adaptive killers: The gamma delta cells' lifestyle;Lymphocytes Tγδ en cancérologie des lymphocytes tueurs non conventionnels

Medecine/Sciences

Volumn 26, Issue 2, 2010, Pages 185-191

  Catros, Véronique ^a   Toutirais, Olivier ^a   Bouet, Françoise ^a   Cabillic, Florian ^a   Desille, Mireille ^a   Fournié, Jean Jacques ^b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE ANTIGEN RECEPTOR; MEVALONIC ACID; PHOSPHOPROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; CHEMISTRY; CLINICAL TRIAL; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; REVIEW; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DIPHOSPHONATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, INNATE; IMMUNOLOGICAL SYNAPSES; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MEVALONIC ACID; MICE; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHOPROTEINS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 77749319495     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2010262185     Document Type: Review

References (35)

1. Catros-Quemener V, Bouet F, Genetet N. Immunité antitumorale et thérapies cellulaires du cancer. Med Sci (Paris) 2003;19:43-53.
2. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
3. Hayday AC. Gamma-delta cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975-1026.
4. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994;264:267-70.
5. Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
6. Boedec A, Sicard H, Dessolin J, et al. Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy- 2-methylbut-2-enyl 4-diphosphate. J Med Chem 2008;51:1747-54.
7. Bouet-Toussaint F, Cabillic F, Toutirais O, et al. Vγ9Vδ2 T cells-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 2008;57:531-9.
8. Corvaisier M, Moreau-Aubry A, Diez E, et al. Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol 2005;175:5481-8.
9. Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vγ9Vδ2T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-1. Immunity 2005;22:71-80.
10. Toutirais O, Cabillic F, Le Friec G, et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells. Eur J Immunol 2009;39:1361-8.
11. Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006;18:539-46.
12. * T regulatory cells in mycobacterial infection. Blood 2009;113:837-45.
13. Salot S, Laplace C, Saiagh S, et al. large scale expansion of gamma9delta2 T lymphocytes: Innacell gammadelta cell therapy product. J Immunol Methods 2007;326:63-75.
14. Viey E, Lucas C, Romagne F, et al. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.J Immunother 2008;31:313-23.
15. Gertner-Dardenne J, Bonnafous C, Bezombes C, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009;113:4875-84.
16. * tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol 1990;20:2685-9.
17. Thomas ML, Samant UC, Deshpande RK, et al. γδT cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol Immunother 2000;48:653-9.
18. ™ activated-γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005;174:1338-47.
19. Zheng BJ, Chan KW, IM S, et al. Anti-tumor effects of human peripheral γδ T cells in a mouse tumor model. Int J Cancer 2001;92:421-5.
20. Wilhem M, Kunzmann V, Eckstein S, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6.
21. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7.
22. Kobayashi H, Tanaka Y, Yogi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469-76.
23. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gammadeltatrade mark, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57:1599-609.
24. Banchereau J. Grandeur et servitude de I'immunologie humaine. Med Sci (Paris) 2008;24:783-6.
25. * Treg cells inhibit human memory gammadelta T cells to produce IFN-gamma in response to M. tuberculosis antigen ESAT-6. Blood 2008;111:5629-36.
26. Sicard H, Ingoure S, Luciani B, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 2005;175:5471-80.
27. Thedrez A, Harly C, Morice A, et al. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vgamma9Vdelta2 T cells for adoptive immunotherapy. J Immunol 2009;182:3423-31.
28. Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 2007;215:123-35.
29. Takahara M, Miyai M, Tomiyama M, et al. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. J Leukoc Biol 2008;83:742-54.
30. Espinosa E, Tabiasco J, Hudrisier D, et al. Synaptic transfer by human gamma delta T cells stimulated with soluble or cellular antigens. J Immunol 2002;168:6336-43.
31. Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007;26:1423-33.
32. Brandes M, Willimann K, Bioley G, et al. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci USA 2009;106:2307-12.
33. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008;118:1991-2001.
34. Chouaib S, El Hage F, Bentalam H, et al. Immunothérapie du cancer: espoirs et rélités. Med Sci (Paris) 2006;22:755-9.
35. Le Deist F, de Saint Basile G, Rieux-Laucat F, Hivroz C, Fischer A. Anomalies d'expression du complexe récepteur T de l'antigène CD3 et déficits immunitaires. Med Sci (Paris) 2007;23:161-6.